Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed James M. O’Brien as Chief Financial Officer (CFO) in the US in connection with the company’s transition to a fully integrated commercial organization. Jim has extensive experience in all aspects of financial management and planning. […]
